Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the Children's Oncology Group

Marcio Malogolowkin, Howard M. Katzenstein, Rebecka L. Meyers, Mark D. Krailo, Jon M. Rowland, Joel Haas, Milton J. Finegold

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Purpose: Children with pure fetal histology (PFH) hepatoblastoma treated with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outcomes when compared with other patients with hepatoblastoma. We prospectively studied the safety and efficacy of reducing therapy in all children with stage I PFH enrolled onto two consecutive studies. Patients and Methods: From August 1989 to December 1992, 9 children with stage I PFH were treated on the Intergroup Hepatoblastoma study INT-0098 and were nonrandomly assigned to receive chemotherapy after surgical resection with single-agent bolus doxorubicin for 3 consecutive days. From March 1999 to November 2006, 16 children with stage I PFH enrolled onto Children's Oncology Group Study P9645 were treated with observation after resection. Central confirmation of the histologic diagnosis by a study group pathologist was mandated. The extent of liver disease was assigned retrospectively according to the pretreatment extent of disease (PRETEXT) system and is designated "retro-PRETEXT" to clarify the retrospective group assignment. Results: Five-year event-free and overall survival for the 9 patients treated on INT-0098 were 100%. All 16 patients enrolled onto the P9645 study were alive and free of disease at the time of last contact, with a median follow-up of 4.9 years. Retro-PRETEXT for the 21 patients with available data revealed seven patients with stage I disease, 10 patients with stage II disease, and four patients with stage III disease. Conclusion: Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is necessary.

Original languageEnglish (US)
Pages (from-to)3301-3306
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number24
DOIs
StatePublished - Aug 20 2011
Externally publishedYes

Fingerprint

Hepatoblastoma
Histology
Drug Therapy
Doxorubicin
Disease-Free Survival
Liver Diseases
Therapeutics
Observation
Safety
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology : A report from the Children's Oncology Group. / Malogolowkin, Marcio; Katzenstein, Howard M.; Meyers, Rebecka L.; Krailo, Mark D.; Rowland, Jon M.; Haas, Joel; Finegold, Milton J.

In: Journal of Clinical Oncology, Vol. 29, No. 24, 20.08.2011, p. 3301-3306.

Research output: Contribution to journalArticle

Malogolowkin, Marcio ; Katzenstein, Howard M. ; Meyers, Rebecka L. ; Krailo, Mark D. ; Rowland, Jon M. ; Haas, Joel ; Finegold, Milton J. / Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology : A report from the Children's Oncology Group. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 24. pp. 3301-3306.
@article{f61d196df27d4d7ebc3cd46c48326b8a,
title = "Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the Children's Oncology Group",
abstract = "Purpose: Children with pure fetal histology (PFH) hepatoblastoma treated with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outcomes when compared with other patients with hepatoblastoma. We prospectively studied the safety and efficacy of reducing therapy in all children with stage I PFH enrolled onto two consecutive studies. Patients and Methods: From August 1989 to December 1992, 9 children with stage I PFH were treated on the Intergroup Hepatoblastoma study INT-0098 and were nonrandomly assigned to receive chemotherapy after surgical resection with single-agent bolus doxorubicin for 3 consecutive days. From March 1999 to November 2006, 16 children with stage I PFH enrolled onto Children's Oncology Group Study P9645 were treated with observation after resection. Central confirmation of the histologic diagnosis by a study group pathologist was mandated. The extent of liver disease was assigned retrospectively according to the pretreatment extent of disease (PRETEXT) system and is designated {"}retro-PRETEXT{"} to clarify the retrospective group assignment. Results: Five-year event-free and overall survival for the 9 patients treated on INT-0098 were 100{\%}. All 16 patients enrolled onto the P9645 study were alive and free of disease at the time of last contact, with a median follow-up of 4.9 years. Retro-PRETEXT for the 21 patients with available data revealed seven patients with stage I disease, 10 patients with stage II disease, and four patients with stage III disease. Conclusion: Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is necessary.",
author = "Marcio Malogolowkin and Katzenstein, {Howard M.} and Meyers, {Rebecka L.} and Krailo, {Mark D.} and Rowland, {Jon M.} and Joel Haas and Finegold, {Milton J.}",
year = "2011",
month = "8",
day = "20",
doi = "10.1200/JCO.2010.29.3837",
language = "English (US)",
volume = "29",
pages = "3301--3306",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology

T2 - A report from the Children's Oncology Group

AU - Malogolowkin, Marcio

AU - Katzenstein, Howard M.

AU - Meyers, Rebecka L.

AU - Krailo, Mark D.

AU - Rowland, Jon M.

AU - Haas, Joel

AU - Finegold, Milton J.

PY - 2011/8/20

Y1 - 2011/8/20

N2 - Purpose: Children with pure fetal histology (PFH) hepatoblastoma treated with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outcomes when compared with other patients with hepatoblastoma. We prospectively studied the safety and efficacy of reducing therapy in all children with stage I PFH enrolled onto two consecutive studies. Patients and Methods: From August 1989 to December 1992, 9 children with stage I PFH were treated on the Intergroup Hepatoblastoma study INT-0098 and were nonrandomly assigned to receive chemotherapy after surgical resection with single-agent bolus doxorubicin for 3 consecutive days. From March 1999 to November 2006, 16 children with stage I PFH enrolled onto Children's Oncology Group Study P9645 were treated with observation after resection. Central confirmation of the histologic diagnosis by a study group pathologist was mandated. The extent of liver disease was assigned retrospectively according to the pretreatment extent of disease (PRETEXT) system and is designated "retro-PRETEXT" to clarify the retrospective group assignment. Results: Five-year event-free and overall survival for the 9 patients treated on INT-0098 were 100%. All 16 patients enrolled onto the P9645 study were alive and free of disease at the time of last contact, with a median follow-up of 4.9 years. Retro-PRETEXT for the 21 patients with available data revealed seven patients with stage I disease, 10 patients with stage II disease, and four patients with stage III disease. Conclusion: Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is necessary.

AB - Purpose: Children with pure fetal histology (PFH) hepatoblastoma treated with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outcomes when compared with other patients with hepatoblastoma. We prospectively studied the safety and efficacy of reducing therapy in all children with stage I PFH enrolled onto two consecutive studies. Patients and Methods: From August 1989 to December 1992, 9 children with stage I PFH were treated on the Intergroup Hepatoblastoma study INT-0098 and were nonrandomly assigned to receive chemotherapy after surgical resection with single-agent bolus doxorubicin for 3 consecutive days. From March 1999 to November 2006, 16 children with stage I PFH enrolled onto Children's Oncology Group Study P9645 were treated with observation after resection. Central confirmation of the histologic diagnosis by a study group pathologist was mandated. The extent of liver disease was assigned retrospectively according to the pretreatment extent of disease (PRETEXT) system and is designated "retro-PRETEXT" to clarify the retrospective group assignment. Results: Five-year event-free and overall survival for the 9 patients treated on INT-0098 were 100%. All 16 patients enrolled onto the P9645 study were alive and free of disease at the time of last contact, with a median follow-up of 4.9 years. Retro-PRETEXT for the 21 patients with available data revealed seven patients with stage I disease, 10 patients with stage II disease, and four patients with stage III disease. Conclusion: Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is necessary.

UR - http://www.scopus.com/inward/record.url?scp=80051964789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051964789&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.29.3837

DO - 10.1200/JCO.2010.29.3837

M3 - Article

C2 - 21768450

AN - SCOPUS:80051964789

VL - 29

SP - 3301

EP - 3306

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -